1. Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.
- Author
-
Liu, Qi, Zhang, Cheng, Ding, Xianting, Deng, Hui, Zhang, Daming, Cui, Wei, Xu, Hongwei, Wang, Yingwei, Xu, Wanhai, Lv, Lei, Zhang, Hongyu, He, Yinghua, Wu, Qiong, Szyf, Moshe, Ho, Chih-Ming, and Zhu, Jingde
- Subjects
Cell Line ,Tumor ,Animals ,Humans ,Mice ,Disease Models ,Animal ,Antineoplastic Agents ,Antineoplastic Combined Chemotherapy Protocols ,Drug Therapy ,Combination ,Tumor Burden ,Drug Evaluation ,Preclinical ,Xenograft Model Antitumor Assays ,Signal Transduction ,Cell Survival ,Drug Resistance ,Neoplasm ,Models ,Theoretical ,Urinary Bladder Neoplasms ,Cancer ,Breast Cancer ,Biotechnology ,Urologic Diseases ,5.1 Pharmaceuticals ,Cell Line ,Tumor ,Disease Models ,Animal ,Drug Therapy ,Combination ,Drug Evaluation ,Preclinical ,Drug Resistance ,Neoplasm ,Models ,Theoretical ,Biochemistry and Cell Biology ,Other Physical Sciences - Abstract
Therapeutic outcomes of combination chemotherapy have not significantly advanced during the past decades. This has been attributed to the formidable challenges of optimizing drug combinations. Testing a matrix of all possible combinations of doses and agents in a single cell line is unfeasible due to the virtually infinite number of possibilities. We utilized the Feedback System Control (FSC) platform, a phenotype oriented approach to test 100 options among 15,625 possible combinations in four rounds of assaying to identify an optimal tri-drug combination in eight distinct chemoresistant bladder cancer cell lines. This combination killed between 82.86% and 99.52% of BCa cells, but only 47.47% of the immortalized benign bladder epithelial cells. Preclinical in vivo verification revealed its markedly enhanced anti-tumor efficacy as compared to its bi- or mono-drug components in cell line-derived tumor xenografts. The collective response of these pathways to component drugs was both cell type- and drug type specific. However, the entire spectrum of pathways triggered by the tri-drug regimen was similar in all four cancer cell lines, explaining its broad spectrum killing of BCa lines, which did not occur with its component drugs. Our findings here suggest that the FSC platform holds promise for optimization of anti-cancer combination chemotherapy.
- Published
- 2015